News

Brian Sheridan, general counsel of the Sorin Group, said: “This settlement, following the US District Court’s denial of ATS’s motion to dismiss, is very favorable to Sorin Group.

Prior to Iomai, he served as president and CEO of Procept, a publicly traded immunology company, as vice president, corporate development at Integrated Genetics (now Genzyme), and in

Mr Moch is the founder and president of Euclidean Life Science Advisors, which provides strategic advisory services to life sciences companies. He is a former managing director of

Thomas Smith, vice president of medical affairs at Teva Neuroscience, said: “The thinner, 29-gauge needle further demonstrates Teva’s commitment to continued research and development of Copaxone to help

Trinity has recently obtained CE marking which enables it to sell the Destiny Max in Europe and has now filed its 510k submission with the FDA seeking permission

According to the company, the new funds will be used to progress its acquisition plan and to establish its US operations in South Carolina to expand its presence

The Menaflex was determined to be substantially equivalent through the premarket notification process and is indicated for use in surgical procedures for the reinforcement and repair of soft

Under the terms of the agreement, Sangamo is expected to provide a worldwide, fully paid, perpetual, royalty free, non-exclusive, license for the use of certain ZFP Nuclease (ZFN) reagents for

ATL-962, which was discovered and created by Alizyme, is expected to be an agent to treat obesity and related diabetes or dyslipidemia through its mechanism of action which